|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 294.55 USD | +1.45% |
|
+17.68% | +59.47% |
| 18/07 | Nomura Adjusts BeOne Medicines Price Target to $352.60 From $347.02, Maintains Buy Rating | MT |
| 18/07 | Nomura Adjusts BeOne Medicines' Price Target to HK$209.92 From HK$206.60, Keeps at Buy | MT |
Company Valuation: BeOne Medicines Ltd.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 23,494 | 27,843 | 22,843 | 18,862 | 19,667 | 34,948 | - | - |
| Change | - | 18.51% | -17.96% | -17.43% | 4.27% | 77.7% | - | - |
| Enterprise Value (EV) 1 | 19,361 | 24,097 | 19,511 | 16,564 | 19,667 | 32,898 | 32,579 | 31,707 |
| Change | - | 24.46% | -19.03% | -15.1% | 18.73% | 67.27% | -0.97% | -2.68% |
| P/E ratio | -13.5x | -17.8x | -11.3x | -21.3x | -30.2x | 187x | 44.4x | 29.1x |
| PBR | 5.57x | 4.03x | 5.17x | 5.32x | - | 8.68x | 7.03x | 5.17x |
| PEG | - | 0.9x | -0.4x | 0.4x | 1.1x | -1x | 0x | 0.6x |
| Capitalization / Revenue | 76.1x | 23.7x | 16.1x | 7.67x | 5.16x | 6.81x | 5.62x | 4.87x |
| EV / Revenue | 62.7x | 20.5x | 13.8x | 6.74x | 5.16x | 6.41x | 5.24x | 4.42x |
| EV / EBITDA | -11.9x | -17.3x | -11.3x | -14.8x | -49.6x | 109x | 39.6x | 22.2x |
| EV / EBIT | -11.7x | -16.7x | -10.9x | -13.7x | -34.6x | 234x | 50.3x | 27.7x |
| EV / FCF | -13.8x | -15.4x | -10.7x | -9.63x | - | -872x | 57.8x | 33.9x |
| FCF Yield | -7.24% | -6.48% | -9.34% | -10.4% | - | -0.11% | 1.73% | 2.95% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -19.13 | -15.23 | -19.43 | -8.45 | -6.12 | 1.574 | 6.64 | 10.11 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 308.9 | 1,176 | 1,416 | 2,459 | 3,810 | 5,132 | 6,221 | 7,181 |
| EBITDA 1 | -1,626 | -1,392 | -1,723 | -1,120 | -396.4 | 301 | 822.9 | 1,427 |
| EBIT 1 | -1,658 | -1,439 | -1,790 | -1,208 | -568.2 | 140.8 | 647.7 | 1,147 |
| Net income 1 | -1,597 | -1,413 | -2,004 | -881.7 | -644.8 | 135.3 | 611.2 | 1,061 |
| Net Debt 1 | -4,132 | -3,746 | -3,332 | -2,297 | - | -2,050 | -2,369 | -3,241 |
| Reference price 2 | 258.39 | 270.93 | 219.94 | 180.36 | 184.71 | 294.55 | 294.55 | 294.55 |
| Nbr of stocks (in thousands) | 90,924 | 102,770 | 103,859 | 104,578 | 106,476 | 118,650 | - | - |
| Announcement Date | 25/2/21 | 25/2/22 | 27/2/23 | 26/2/24 | 27/2/25 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 187.15x | 6.41x | 109.3x | -.--% | 34.95B | ||
| 39.36x | 5.74x | 20.13x | 0.87% | 50.35B | ||
| 46.97x | 9.52x | 28.42x | 0.4% | 28.67B | ||
| 21.47x | 2.51x | 10.63x | -.--% | 27.79B | ||
| 24.43x | 1.98x | 8.97x | 1.08% | 12.81B | ||
| 15.36x | 1.76x | 8.84x | -.--% | 11.41B | ||
| -40.18x | 8.92x | 2158.78x | -.--% | 10.56B | ||
| 25.53x | 5.26x | 13.96x | 0.31% | 10.47B | ||
| -41.26x | 14.54x | -55.6x | -.--% | 10.29B | ||
| 24.48x | 3.91x | 18.05x | -.--% | 8.96B | ||
| Average | 30.33x | 6.06x | 232.15x | 0.26% | 20.63B | |
| Weighted average by Cap. | 51.35x | 5.99x | 139.07x | 0.35% |
Year-on-year evolution of the PER
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- ONC Stock
- Valuation BeOne Medicines Ltd.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition